View Main Condition: Mucopolysaccharidoses (MPS)
Mucopolysaccharidosis type I (MPS I) is a condition that affects many parts of the body. This disorder was once divided into three separate syndromes: Hurler syndrome (MPS I-H), Hurler-Scheie syndrome (MPS I-H/S), and Scheie syndrome (MPS I-S), listed from most to least severe. Because there is so much overlap between each of these three syndromes, MPS I is currently divided into the severe and attenuated types.
Mutations in the IDUA gene cause MPS I. The IDUA gene provides instructions for producing an enzyme that is involved in the breakdown of large sugar molecules called glycosaminoglycans (GAGs). GAGs were originally called mucopolysaccharides, which is where this condition gets its name. Mutations in the IDUA gene reduce or completely eliminate the function of the IDUA enzyme. The lack of IDUA enzyme activity leads to the accumulation of GAGs within cells, specifically inside the lysosomes. Lysosomes are compartments in the cell that digest and recycle different types of molecules. Conditions that cause molecules to build up inside the lysosomes, including MPS I, are called lysosomal storage disorders. The accumulation of GAGs increases the size of the lysosomes, which is why many tissues and organs are enlarged in this disorder. Researchers believe that the GAGs may also interfere with the functions of other proteins inside the lysosomes and disrupt the movement of molecules inside the cell.
Severe MPS I occurs in approximately 1 in 100,000 newborns. Attenuated MPS I is less common and occurs in about 1 in 500,000 newborns.
This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.
Patricia Dickson is a Pediatrics specialist and a Medical Genetics expert in Saint Louis, Missouri. Dickson has been practicing medicine for over 24 years and is rated as an Elite expert by MediFind in the treatment of Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome). She is also highly rated in 5 other conditions, according to our data. Her top areas of expertise are Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 3 (MPS III, Sanfilippo Syndrome), Mucopolysaccharidosis Type 3B (MPS IIIB, Sanfilippo Syndrome B), and Hip Replacement. She is licensed to treat patients in Missouri. Dickson is currently accepting new patients.
Chester Whitley is a Pediatrics specialist and a Medical Genetics expert in Minneapolis, Minnesota. Whitley has been practicing medicine for over 43 years and is rated as an Elite expert by MediFind in the treatment of Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome). He is also highly rated in 34 other conditions, according to our data. His top areas of expertise are Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), Gangliosidosis, and GM1 Gangliosidosis. He is licensed to treat patients in Minnesota. Whitley is currently accepting new patients.
Paul Orchard is a Pediatric Hematologist Oncology specialist and a Pediatrics expert in Minneapolis, MN. Orchard has been practicing medicine for over 39 years and is rated as an Elite expert by MediFind in the treatment of Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome). He is also highly rated in 34 other conditions, according to our data. His top areas of expertise are Adrenoleukodystrophy (ALD), Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), Leukodystrophy, Mucopolysaccharidoses (MPS), and Bone Marrow Transplant. He is board certified in Pediatrics and licensed to treat patients in Minnesota. Orchard is currently accepting new patients.
Summary: Phase I/II, open label, multicenter, multinational (Japan, Brazil and the US) extension study of JR-171-101 for the treatment of MPS I
Summary: This is a prospective, observational multicenter study to collect blood from patients with mucopolysaccharidosis type IH undergoing laronidase therapy and a stem cell transplant. Sixteen patients will be enrolled over a 24 month period.
Published Date: December 01, 2012Published By: National Institutes of Health